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Essential hypertension is characterized by increased peripheral vascular resistance to blood ﬂow. The endothelium is a crucial
regulator of vascular tone. Its function is impaired in patients with hypertension, with reduced vasodilation, increased vascular
tone associated with a proinﬂammatory and prothrombotic state. Low-grade inﬂammation localized in vascular tissue is therefore
recognizedasanimportantcontributortothepathophysiologyofhypertension,totheinitiationandprogressionofatherosclerosis
as well as to the development of cardiovascular diseases.
1.Introduction
Vascular remodeling and increased peripheral vascular resis-
tance to blood ﬂow are common features of essential hyper-
tension. Resistance arteries may play an important role in the
development [1] and may contribute to the complications of
hypertension [2]. Small decrease in the lumen of the small
arteries signiﬁcantly increases resistance to blood ﬂow. Vas-
cular tone is regulated by the endothelium, which may aﬀect
vascular function and remodeling. Endothelium is the active
inner monolayer of the blood vessels, forming an interface
between circulating blood and the vessel wall. It represents
the largest organ in the body and plays a critical role in
vascularhomeostasis. Endothelial cellsregulatevasculartone
by releasing various contracting and relaxing factors includ-
ing nitric oxide (NO), arachidonic acid metabolites, reactive
oxygen species (ROS), and vasoactive peptides. Therefore,
the endothelium actively regulates vascular tone and perme-
ability, the balance between coagulation and ﬁbrinolysis, the
inﬂammatory activity as well as cell proliferation. Endothe-
lial dysfunction is characterized by impaired vasomotor
response (reduced vasodilation and increased endothelium-
dependent contraction), cell proliferation, platelet activa-
tion, vascular permeability, and a proinﬂammatory and
prothrombotic phenotype, including leucocyte-endothelial
interactions that participate in vascular inﬂammation and
increased adhesion and aggregation of platelets [3].
Endothelial progenitor cells (EPCs), a bone-marrow-
derived population of cells which can develop into com-
petent mature endothelial cells [4] ,a r es e e na sa ni m p o r -
tant determinant of endothelial function. Decreased EPCs
number is associated with arterial stiﬀness [4] and decreased
endothelial function [5]. In this regard, it has been shown
that circulating EPCs are signiﬁcantly reduced in hyper-
tensive type 2 diabetic patients [4] and in salt-loaded
hypertensive rats [5].
Endothelial dysfunction occurs in association with
several cardiovascular risk factors. Hypercholesterolemia,
hypertension, and insulin resistance contribute to endothe-
lial dysfunction and inﬂammation in the vascular wall, as
wellastoincreasedlipoproteinoxidation,smoothmusclecell
proliferation, extracellular matrix deposition, cell adhesion,
and thrombus formation [6–8]. Thus, endothelial dysfunc-
tion may be involved in the initiation of vascular inﬂamma-
tion,inthedevelopmentofvascularremodeling,itisanearly
determinant in the progression to atherosclerosis, and it is2 International Journal of Hypertension
independently associated with increased cardiovascular risk
[9–12].
Endothelial dysfunction promotes vascular inﬂamma-
tion by inducing the production of vasoconstrictor agents,
adhesion molecules, and growth factors including angi-
otensin II (Ang II) and endothelin 1 [6, 8]. Ang II, one of
the ﬁnal products of the renin-angiotensin system (RAS),
is actively involved in the pathophysiology of hypertension
[13]. It may be responsible for triggering endothelial dys-
function and vascular inﬂammation by inducing oxidative
stress, resulting in upregulation of inﬂammatory mediators
and cell-growth.
Low-grade inﬂammation in the vascular wall is an
important contributor to the pathophysiology of hyperten-
sion [14], atherosclerosis, and the development of cardio-
vascular disease (CVD) [11, 15]. Patients with CVD present
with increased expression and plasma concentration of
inﬂammatory markers and mediators [16, 17]. In particular,
increased plasma levels of TNF-a (tumour necrosis factor-a),
IL (interleukin)-6, as well as the adhesion molecules ICAM-
1 (intercellular adhesion molecule-1), VCAM-1 (vascular
cell adhesion molecule-1), and E-selectin, as well as vWF
(von Willebrand factor) and CRP (C-reactive protein), have
been demonstrated [18–20] in hypertensive subjects. Thus
inﬂammation is a central mechanism contributing to the
progression of CVD, and may be involved in the triggering
of myocardial and cerebrovascular ischemia [8, 21].
In this paper we discuss the role of the low-grade




Blood pressure itself or RAS activation [16] may induce
the inﬂammatory process, which participates to vascular
remodeling and may contribute to accelerated vascular
damage in aging and CVD. Endothelial dysfunction is an
early determinant in the development of hypertension, in
the progression to atherosclerosis and is independently
associated with increased cardiovascular risk [9]. Essential
hypertension is characterized by increased peripheral vascu-
lar resistance to blood ﬂow, which occurs mostly as a result
of energy dissipation in small resistance arteries, particularly
in younger individuals. Enhanced constriction of resistance
arteriesmayincreaseperipheralresistanceinhypertensionby
reducing lumen diameter [22]. Endothelial dysfunction may
participate to the increased vascular tone in hypertension
[10], with reduced vasodilation associated with a proinﬂam-
matory and prothrombotic state. Moreover, in hypertension,
resistance arteries undergo vascular remodeling (reduced
lumen with increased media width) that may be structural,
mechanical, or functional. Extracellular matrix deposition
and inﬂammation are critically involved in vascular remod-
eling. With chronic vasoconstriction (due to increased
myogenic tone, RAS activation, catecholamines, and growth
factors production), vessels may become embedded in the
remodeled extracellular matrix and may not return to their
vasodilated state [23]. Chronically elevated blood pressure
and stretch induce complex signal transduction cascades
leading to vascular remodeling that contributes not only to
elevation of blood pressure but also to hypertensive com-
plications [24]. Arterial hypertension as well as aging and
other cardiovascular risk factors may also increase arterial
stiﬀness in large conduit arteries, which is associated with
both target organ damage and increased risk for cardio-
vascular morbidity and mortality [25]. Inﬂammation of
large arteries exerts its eﬀects in part by contributing to
endothelial dysfunction and by increasing vascular stiﬀness,
in the presence or absence of hypertension.
Inﬂammation contributes to vascular remodeling pro-
moting cell growth and proliferation of vascular smooth
muscle cells (VSMCs). This is supported by the increased
expression in the vascular wall of adhesion molecules and
ligands, leukocyte extravasation, increased oxidative stress,
cytokine production, activation of immune cells and pro-
inﬂammatory signaling pathways. Greater expression of
adhesion molecules (VCAM-1, ICAM-1) on the endothelial
cell membrane, accumulation of monocyte/macrophages,
dendritic cells, natural killer cells, and B and T lymphocytes
participate to the inﬂammatory response in the vascular wall
[26]. Patients with CVD present increased expression and
plasma concentration of inﬂammatory markers and medi-
ators [17, 21, 27]. High levels of inﬂammatory mediators
(IL-6, ICAM-1, and CRP) may be independent risk factors
for the development of hypertension [18, 19]. Moreover they
have been associated with increased risk of diabetes [20]a n d
CVD. In particular CRP measured with a high-sensitivity
assay (hsCRP) has been related to insulin resistance, systolic
blood pressure, pulse pressure (PP, an index of arterial
stiﬀness) [28, 29], and to markers of endothelial dysfunction
including plasma levels of vWF, tissue plasminogen activator
and cellular ﬁbronectin [30]. Plasma hsCRP level is a strong
predictor of ischemic cardiovascular events in patients with
stable or unstable angina; it correlates with vulnerable
plaques, and it may as well predict cardiovascular events
among apparently healthy subjects [31–33].
Innate immunity may play a role in the mechanisms that
contributetothelow-gradeinﬂammatoryresponseinhyper-
tension. In mice deﬁcient in vascular macrophages (due to a
mutation in the mCSF gene) Ang II and deoxycorticosterone
acetate-(DOCA-) salt were not able to induce hypertension
or vascular remodeling [14]. Moreover, mice deﬁcient in T
and B lymphocytes presented blunted hypertensive response
to Ang II and DOCA-salt [34]. Reduced vascular remodeling
in response to Ang II was also observed [34]. The lack
of response to Ang II was corrected by eﬀector T cell
but not by B lymphocyte adoptive transfer. Moreover, the
central and pressor eﬀects of Ang II are critical for T-cell
activation and the development of vascular inﬂammation
[35]. T lymphocytes may participate in hypertension and
peripheral inﬂammation possibly by the increased produc-
tion of oxidative stress [36]. A role of T regulatory (Treg)
lymphocytes in blood pressure regulation and vascular
inﬂammation has also been described. It has been recently
shown that Treg adoptive transfer lowered blood pressure
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either Ang II or aldosterone. It has been recently showed that
adoptive immunity may be enhanced as a result of a genetic
predisposition with loci on chromosome 2 (which carries
many pro-inﬂammatory genes) [37] in a consomic strain
of rats (SSBN2), which contains the genetic background
of hypertensive Dahl salt-sensitive rats and chromosome
2 from Brown-Norway normotensive rats. The presence
of the normotensive chromosome 2 was associated with
upregulationofTregmarkers(CD8+andCD4+lymphocytes
which were CD25+). Those markers were depressed in
the Dahl salt-sensitive rats. Enhanced Treg and increased
expression of the transcription factor Foxp3 (a marker of
Treg)aswellasIL-10andTGF(transforminggrowthfactor)-
beta production (produced by Treg) were found in consomic
rats and the opposite in Dahl rats. The potential protective
role of Treg in cardiovascular disease is further supported by
the evidence that adoptive transfer of Treg cells ameliorated
cardiac damage and improved eutrophic remodeling in Ang
II-infused mice, independently of blood-pressure-lowering
eﬀects[27].ThissuggestsaroleofTreginthepathogenesisof
blood-pressure-induced cardiovascular remodeling. Hence,
diﬀerent subsets of T lymphocytes may be involved in the
mechanisms leading to the inﬂammatory response described
in cardiac and metabolic diseases when an imbalance exists
between the pro-inﬂammatory Th1, Th2, and Th17 and the
antiinﬂammatory Treg subsets [27].
3. Role of Renin-AngiotensinSystem in
Vascular Damage
Ang II plays a key role in the pathophysiology of hyper-
tension [24] and CVD by inducing vascular remodeling
and injury. Several mechanisms may be activated by Ang
II such as endothelial dysfunction, vasoconstriction, cell
growth,oxidativestress,andinﬂammation.AngIIstimulates
cell growth by inducing hyperplasia and hypertrophy of
VSMCs from resistance arteries of patients with essential
hypertension and from small arteries of hypertensive rats.
In hypertension, Ang II may enhance basal superoxide
production in the vasculature by activation of reduced
NADPH (Nicotinamide Adenine Dinucleotide Phosphate)
oxidase and expression of its subunits via cSrc, PKC (Protein
Kinase C), PLA2 (Phospholipase A2), and PLD (Phospholi-
pase D) pathways [38–41]. These processes may contribute
to increased activation of NADPH oxidase and, in turn, to
enhanced oxidative stress in the vascular wall [10]. NADPH
oxidase is the major source of ROS in the vascular wall.
It is expressed in endothelial cells, VSMCs, ﬁbroblasts, and
monocytes/macrophages [42, 43]. Increased Ang II-induced
ROS generation is involved in the process of vascular remod-
eling. This occurs by VSMC proliferation and hypertrophy,
collagen deposition, and by modulating cytokine release
and pro-inﬂammatory transcription factors. ROS activate
multiple signaling molecules including mitogen-activated
protein kinases (MAP-kinases); nonreceptor tyrosine kinases
suchasSrc,JAK-2(JanusKinase2),STAT(SignalTransducer
and Activator of Transcription), p21Ras, Pyk-2 (Proline-rich
TyrosineKinase2),andAkt;receptortyrosinekinases(EGFR
(Epidermal Growth Factor Receptor), IGFR (Insulin-like
Growth Factor Receptor 1), and PDGFR (Platelet-Derived
Growth Factor Receptor); protein tyrosine phosphatases and
redox-sensitivetranscriptorfactors(NuclearFactor(NF)-κB,
Activator Protein 1 (AP)-1 and Hypoxia-inducible factor 1
(HIF-1)) [42, 44]. Thus, ROS act as signaling molecules,
modulating vascular tone and structural changes in the
vasculature [39] and participate in the development and
progression of atherosclerosis [44]. In addition, ROS reduce
thevascularbioavailabilityofNO[45,46]whichisassociated
with impaired endothelium-dependent vascular relaxation
and increased vascular contractile responses. Moreover this
is also associated to structural changes in the wall of small
arteries and to the increased peripheral vascular resistance
[47]. Ang II-induced ROS production increases ICAM-1
expression, macrophage inﬁltration, monocyte chemotactic
protein (MCP)-1 production, and vascular hypertrophy,
independentlyofbloodpressureelevation[48].Furthermore
Ang II stimulates the production of E-selectin through
redox-dependent pathways [48] and PAI-1, which con-
tributes to a prothrombotic state as well as to atherosclerotic
plaque rupture. Moreover, macrophages which inﬁltrate
the adventitia or the media of blood vessels may generate
oxidative stress by NADPH oxidase [48, 49].
Ang II-induced growth and proﬁbrotic eﬀects are par-
tially modulated by endogenous production of mitogenic
factors (including TGF-β, PDGF (platelet-derived growth
factor), EGF (epidermal growth factor), IGF-1 (insulin-like
growth factor 1) and endothelin-1) [50, 51]. In particular
TGF-β is produced by macrophages, lymphocytes, ﬁbrob-
lasts, VSMCs and is overexpressed in many cardiovascular
and renal disorders associated with activation of the RAS.
TGF-β increases extracellular matrix biosynthesis, downreg-
ulates matrix degradative enzymes, and inﬂuences integrin
receptors [52, 53]. p38MAP kinase and connective tissue
growth factor are among the major downstream proﬁbro-
genic mediators of TGF-β. Inhibition of the RAS with ACE
inhibitors or ARBs is directly correlated with suppression of
TGF-β production and amelioration of ﬁbrosis [52, 54].
Inﬂammation may activate the RAS, which in turn may
further contribute to vascular remodeling in hypertension.
Activators of nuclear receptors, such as the peroxisome
proliferator-activated receptors (PPARs), downregulate the
vascular inﬂammatory response in experimental animals
[55]anddecreaseserummarkersofinﬂammationinhumans
[56]. Hence, PPARs may be endogenous modulators of the
inﬂammatoryprocessinvolvedinvascularstructuralchanges
in hypertension. On the other hand, Ang II downregulates
PPARs through activation of NF-κB[ 57].
Ang II may also play a role in EPC production. This
eﬀect may be dependent on the duration of Ang II exposure
[58]. Acute Ang II administration via AT1Rs y n e r g i s t i -
cally increases vascular endothelial growth factor-(VEGF-)
induced proliferation of EPCs [59]. Moreover, in Ang II-
infused mice or in a clipped kidney mouse model of hyper-
tension, the number of circulating EPCs increased. This may
be dependent on an increase in cell proliferation as well as on
a reduction in apoptosis via Akt and eNOS-derived NO pro-
duction [60]. AT1R antagonism blocked this eﬀect [61]. On4 International Journal of Hypertension
the other hand, it has been also shown that Ang II decreases
EPC number. Infusion of Ang II in rats is associated with
decreased EPC number that is reversible by treatment with
an ARB [62]. AT1R blockade increased EPC numbers in type
2 diabetic patients [5]. Infusion of Ang II in rats signiﬁcantly
reduced telomerase activity and accelerated the onset of
cellularsenescenceinEPCs,suggestingthatreductioninEPC
levels after Ang II infusion results from impaired EPC prolif-
eration.StudiesinculturedEPCssuggestthatthemechanism
of Ang II-mediated EPC senescence may also involve ROS
[63]. In these cells, the induction of EPC senescence was
found to be associated with NADPH oxidase-dependent
generation of ROS. Indeed, treatment with superoxide
dismutase (SOD) blocked Ang II-mediated EPC senescence.
ROS are potent stimulators of endothelin-1 synthesis
by endothelial cells and VSMCs [64]. Endothelin-1 in turn
activates NADPH oxidase as well as other sources of ROS,
such as xanthine oxidase and mitochondria, in VSMCs and
blood vessels [65–67]. Moreover, Ang II-induced inﬂamma-
tion via NF-κB and AP-1 activation involves in part endothe-
lin receptors [68]. Endothelin-1-induced oxidative stress
promotes inﬂammatory responses and in turn contributes
to the vascular remodeling and endothelial dysfunction in
animal models of hypertension that present an endothelin-
mediated component [69]. ETA (Endothelin A) receptor
antagonism decreases oxidative stress, normalizes hyper-
trophicremodeling,decreasescollagenandﬁbronectindepo-
sition, and reduces adhesion molecules in the vasculature of
aldosterone-infused rats [70]. Endothelial dysfunction and
increased activity of NADPH oxidase were described [68]i n
miceoverexpressingpreproendothelin-1 intheendothelium.
This was associated with enhanced oxidative stress and
vascular inﬂammation [68] and, in turn, to increased
arterial stiﬀness as well as to increased collagen deposition,
independently of blood pressure [68]. In humans, exogenous
endothelin-1hasalsobeenshowntoincreasearterialstiﬀness
[71, 72]. Hence, in endothelial dysfunction where NO is
downregulated and endothelin-1 upregulated, the balance is
shifted in favor of increased arterial stiﬀness.
Ang II induces aldosterone synthesis which in turn
increases tissue ACE activity [73] and up-regulates angio-
tensin receptors [74]. The activation of mineralocorticoid
receptors may contribute to cardiovascular dysfunction,
inﬂammation, ﬁbrosis, and vascular damage. Several animal
models have conﬁrmed that aldosterone may induce ROS
formation and endothelial dysfunction, and therefore it
can cause injury of the vasculature of the brain, heart,
and kidneys [75]. Endothelial dysfunction and inﬂamma-
tion induced by aldosterone may involve the activation
of COX-2 (cyclooxygenase-2) in normotensive and hyper-
t e n s i v er a t s[ 76]. Mineralocorticoid antagonism attenuates
the aldosterone-induced damage by reducing the direct
proinﬂammatory and pro-ﬁbrotic eﬀects of aldosterone that
may be mediated via activation of the endothelin system
[70, 77–79]. Mineralocorticoid receptor blockade may also
improve endothelial function and reduce oxidative stress in
Ang II-infused rats [80]. This suggests that aldosterone may
induce in part actions usually attributed to direct eﬀects of
Ang II in the vasculature.
4. New Biomarkersof Vascular Damage
Several studies indicate that the microparticles of endothelial
origin may be considered as biomarkers of vascular dysfunc-
tion. Microparticles are small vesicular fragments (<1μm) of
cellular membranes derived from most cell types including
endothelial and inﬂammatory cells. They are released in
response to activation, injury, and apoptosis [81]. Micropar-
ticles circulate in the plasma of healthy individuals, and
their levels increase in cardiovascular and atherothrombotic
diseases [82]. Microparticles may contribute to vascular
disease progression in hypertension. In patients with severe
hypertension plasma levels of microparticles correlated with
systolic and diastolic blood pressure [83]. In patients with
diabetes, endothelial microparticle levels are a strong predic-
tor of myocardial infarction and correlate with arterial stiﬀ-
ness and endothelium-mediated vasodilation [84, 85]. They
also relate to the extent and severity of coronary stenosis in
patients with coronary syndromes [86]. In vitro endothelial
microparticles are released in response to inﬂammatory
stimuli [87] (including TNF-α, thrombin, uremic toxins,
ROS, and PAI-1). Although the precise mechanism leading
to generation of microparticles from endothelial cells is not
fully understood, there are pieces of evidences that endothe-
lial NO synthase uncoupling and low shear stress as well [88,
89] enhance their production. Microparticles in turn may
contribute in part to endothelial dysfunction itself through
the activation of ROS production [90, 91]. Microparticles
are capable of impairing vasorelaxation. They interfere
with target cell responses by transferring chemokines and
adhesion molecules to endothelial cells leading to monocyte
adhesion [92] and therefore contributing to vascular injury
in hypertension. Ang II mayinduce microparticle formation,
although the evidences are controversial. Ang II type 1
receptor (AT1R) blockade is associated with a reduction
in the number of monocyte, platelet, and endothelial cell-
derived microparticles in hypertensive diabetic patients [93–
95]. However Ang II administration in cultured HUVEC did
not result in an increased microparticles formation [96].
5. Conclusion
Functional and structural alterations of resistance arter-
ies are the earliest vascular alterations that may occur
in hypertension. Low-grade inﬂammation and endothelial
dysfunction are strictly associated in the development of
hypertension and its complications. The activation of RAS
plays a key role in the genesis of endothelial dysfunction
and vascular remodeling. Ang II activates redox-sensitive
pathways and promotes cell growth and inﬂammation,
involving, in part, factors derived from microparticles and
EPCs. Antihypertensive agents have been shown to partially
correct the vascular remodeling and impaired endothelial
function particularly of small resistance arteries in both
experimental models and human hypertension. In particular
antihypertensive drugs that antagonize RAS, including ACE
inhibitors, ARBs, mineralocorticoid receptor antagonists,
and the renin inhibitors, embody valid therapeutic tools toInternational Journal of Hypertension 5
improve vascular function and reduce vascular remodeling
and cardiovascular risk.
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